磁场抑制肿瘤的机理

综述了磁场抑制肿瘤的机理。磁场可以抑制肿瘤组织的供血与代谢,损伤肿瘤细胞的DNA,诱导肿瘤细胞凋亡,以及增强机体对肿瘤的免疫作用等。     

磁场对肿瘤抑制作用的研究进展

本文综述了从近年来国内外的各类关于磁场抑制肿瘤的实验研究以及临床工作,包括肿瘤细胞实验、动物接种肿瘤实验、临床治疗探索、各类模型以及机理研究、相关物理机制的分析以及磁场治疗癌症的展望。     

静磁场对小鼠黑色素瘤细胞B16生长和氧化应激的影响

目的:利用小鼠黑色素瘤细胞B16,研究静磁场对肿瘤细胞生长和氧化应激的影响,探讨氧化应激介导静磁场影响肿瘤细胞生长的机制,为磁场在肿瘤疾病的治疗中的应用提供理论依据。方法:采用MTT法测定磁场对B16细胞活力的影响;利用流式细胞仪测定静磁场暴露对B16细胞周期分布的影响;利用生物化学方法测定磁场暴露对细胞氧化防御系统相关蛋白酶活性的影响。结果:24 h内50 m T-200 m T静磁场暴露可以抑制B16生长,但超过24 h的磁场暴露可以促进B16生长;100 m T和200 m T静磁场暴露对B16的细胞周期分布没有影响;B16暴露于100 m T和200 m T静磁场48 h,GST活性和GSH/GSSG水平表现为先上升后下降,SOD活性和T-AOC水平先下降后上升,CAT活性没有受到影响。结论:50 m T-200 m T静磁场可以抑制小鼠黑色素瘤细胞B16的生长,诱导肿瘤细胞产生氧化应激。     

稳恒磁场抑制肿瘤增殖的实验研究与理论探讨

作为模型处理最简单的稳恒磁场,其与肿瘤作用的研究是最具理论和实际意义的。分别介绍了稳恒磁场作用于微循环系统、免疫系统对肿瘤的间接抑制和杀伤作用,磁场影响自由基代谢和细胞膜及细胞内结构对肿瘤的抑制作用;回顾了磁场干扰细胞周期、诱导细胞凋亡对肿瘤的影响,并介绍了稳恒磁场联合抗癌药物在治癌中的应用现状;最后结合实验的进展情况,分析探讨了稳恒磁场抑制肿瘤细胞增殖的物理机理,对肿瘤磁疗的发展前景进行了展望。     

稳恒磁场抑制肿瘤增殖的实验研究与理论探讨

作为模型处理最简单的稳恒磁场,其与肿瘤作用的研究是最具理论和实际意义的.分别介绍了稳恒磁场作用于微循环系统、免疫系统对肿瘤的间接抑制和杀伤作用,磁场影响自由基代谢和细胞膜及细胞内结构对肿瘤的抑制作用;回顾了磁场干扰细胞周期、诱导细胞凋亡对肿瘤的影响,并介绍了稳恒磁场联合抗癌药物在治癌中的应用现状;最后结合实验的进展情况,分析探讨了稳恒磁场抑制肿瘤细胞增殖的物理机理,对肿瘤磁疗的发展前景进行了展望.     

稳恒磁场联合抗肿瘤药物协同杀伤肝癌细胞Hepa1-6

化学疗法为肿瘤临床治疗的常规方法,存在毒副作用大、抗药性强等缺陷。为了提高药物的利用效率,减少药物引起的毒副作用,将8.8 m T稳恒磁场分别与顺铂、阿霉素联用,经MTT检测发现磁场与药物联用可对肝癌细胞Hepa1-6生长具有协同抑制的效应,经HE染色发现联合处理组细胞发生明显的形态学改变。流式细胞仪检测显示磁场能增加顺铂对G2/M期细胞的滞留,而磁场与阿霉素共同作用可将细胞阻止于G1期和G2/M期。经彗星电泳检测表明磁场能够增强药物对DNA的损伤,且原子力显微镜观察发现联合处理组细胞膜表面出现较大且较深的孔洞,表面结构破坏严重。实验结果表明,抗肿瘤药物与磁场联用技术可有效抑制肿瘤细胞的生长,减少药物的使用浓度,为将抗肿瘤药物与磁场应用于临床治疗恶性肿瘤提供了一个全新的思路与策略。     

肿瘤转移过程中相关基因的研究进展

肿瘤细胞转移相关基因的激活和／或转移抑制相关基因的失活均可诱发肿瘤细胞转移表型而导致转移的发生。肿瘤细胞成瘤性和转移性分别受“转移相关基因”和“转移抑制相关基因”的调控。本就肿瘤转移的细胞学基础,肿瘤转移相关基因的研究及肿瘤转移抑制相关基因的研究进行了综述。     

苦参活性成分的抗肿瘤作用机制研究进展

苦参是中国传统的植物药,具有清热燥湿等多种作用,广泛地应用于抗肿瘤研究,其活性成分能够通过细胞周期阻滞抑制肿瘤细胞的增殖、诱导肿瘤细胞分化、通过细胞周期阻滞、Fas/Fasl和线粒体途径诱导肿瘤细胞凋亡,通过降低VEGF等的表达抑制肿瘤血管生成和内皮细胞增殖,抑制肿瘤侵袭和转移,通过抑制端粒酶活性、逆转多药耐药、调节免疫耐受等辅助治疗肿瘤。通过收集、分析和整理最近几年涉及苦参活性成分抗肿瘤作用的文献,综述其抗肿瘤作用机制,为临床应用苦参治疗肿瘤提供参考。     

诱杀受体3——肿瘤基因治疗的新靶点

诱杀受体3（DcR3）又称肿瘤坏死因子受体（TNFR）6B,是最近发现的TNFR超家族成员之一。DcR3是一种凋亡抑制蛋白,能够抑制肿瘤细胞凋亡,促进肿瘤细胞免疫逃避。研究显示,DcR3在人类正常分化组织中很少表达,却特异性表达在常见的肿瘤,它的表达上调可预示肿瘤恶性程度和预后。作为肿瘤分子标志物,体液及组织中高水平的DcR3表达能够辅助肿瘤诊断和治疗监测。应用分子生物技术可以抑制肿瘤细胞中DcR3的表达,从而诱导肿瘤细胞的凋亡。     

磁场对恶性肿瘤生长的抑制作用

宿主和恶性肿瘤之间的相互作用和生物电磁现象有关。磁场影响肿瘤生长的报道较多,由于磁场的生物效应及其机制都很复杂,进一步研究工作是需要的,我们观测到一定参数的脉冲梯度磁场在不同生物层次上抑制鼠恶性肿瘤生长,磁场诱发癌细胞凋亡和阻塞供应肿瘤的新生血管,由于脉冲梯度磁场抑制癌生长,所以它能成为一种辅助治疗癌症的新方法。     

Experimental studies on ultralow frequency pulsed gradient magnetic field inducing apoptosis of cancer cell and inhibiting growth of cancer cell

The morphology characteristics of cell apoptosis of the malignant tumour cells in magnetic field-treated mouse was observed for the first time. The apoptotic cancer cell contracted, became rounder and divorced from adjacent cells; the heterochromatin condensed and coagulated together along the inner side of the nuclear membrane; the endoplasmic reticulums(ER) expanded and fused with the cellular membrane; many apoptotic bodies which were packed by the cellular membrane appeared and were devoured by some lymphocytes and plasma. Apoptosis of cancer cells was detected by terminal deoxynucleotidyl transferase mediated in situ nick end labeling(TUNEL). It was found that the number of apoptosis cancer cells of the sample treated by the magnetic field is more than that of the control sample. The growth of malignant tumour in mice was inhibited and the ability of immune cell to dissolve cancer cells was improved by ultralow frequency(ULF) pulsed gradient magnetic field; the nuclei DNA contents decreased, indicating that magnetic field can block DNA replication and inhibit mitosis of cancer cells. It was suggested that magnetic field could inhibit the metabolism of cancer cell, lower its malignancy, and restrain its rapid and heteromorphic growth. Since ULF pulsed gradient magnetic field can induce apoptosis of cancer cells and inhibit the growth of malignant tumour, it could be used as a new method to treat cancer.     

Experimental studies on ultralow frequency pulsed gradient magnetic field inducing apoptosis of cancer cell and inhibiting growth of cancer cell

The morphology characteristics of cell apoptosis of the malignant tumour cells in magnetic field-treated mouse was observed for the first time. The apoptotic cancer cell contracted, became rounder and divorced from adjacent cells; the heterochromatin condensed and coagulated together along the inner side of the nuclear membrane; the endoplasmic reticulums (ER) expanded and fused with the cellular membrane; many apoptotic bodies which were packed by the cellular membrane appeared and were devoured by some lymphocytes and plasma. Apoptosis of cancer cells was detected by terminal deoxynucleotidyl transferase mediated in situ nick end labeling (TUNEL). It was found that the number of apoptosis cancer cells of the sample treated by the magnetic field is more than that of the control sample. The growth of malignant tumour in mice was inhibited and the ability of immune cell to dissolve cancer cells was improved by ultralow frequency (ULF) pulsed gradient magnetic field; the nuclei DNA contents decreased, indi     

A metabolomics perspective of human brain tumours

During the past decade or so, a wealth of information about metabolites in various human brain tumour preparations (cultured cells, tissue specimens, tumours in vivo) has been accumulated by global profiling tools. Such holistic approaches to cellular biochemistry have been termed metabolomics. Inherent and specific metabolic profiles of major brain tumour cell types, as determined by proton nuclear magnetic resonance spectroscopy ((1)H MRS), have also been used to define metabolite phenotypes in tumours in vivo. This minireview examines the recent advances in the field of human brain tumour metabolomics research, including advances in MRS and mass spectrometry technologies, and data analysis.     

Perspectives of the AMP-activated kinase (AMPK) signalling pathway in thyroid cancer

Approximately 90% of non-medullary thyroid malignancies originate from the follicular cell and are classified as papillary or follicular (well-differentiated) thyroid carcinomas, showing an overall favourable prognosis. However, recurrence or persistence of the disease occurs in some cases associated with the presence of loco-regional or distant metastatic lesions that generally become resistant to radioiodine therapy, while glucose uptake and metabolism are increased. Recent advances in the field of tumor progression have shown that CTC (circulating tumour cells) are metabolic and genetically heterogeneous. There is now special interest in unravelling the mechanisms that allow the reminiscence of dormant tumour lesions that might be related to late disease progression and increased risk of recurrence. AMPK (AMP-activated protein kinase) is activated by the depletion in cellular energy levels and allows adaptive changes in cell metabolism that are fundamental for cell survival in a stressful environment; nevertheless, the activation of this kinase also decreases cell proliferation rate and induces tumour cell apoptosis. In the thyroid field, AMPK emerged as a novel important intracellular pathway, since it regulates both iodide and glucose uptakes in normal thyroid cells. Furthermore, it has recently been demonstrated that the AMPK pathway is highly activated in papillary thyroid carcinomas, although the clinical significance of these findings remains elusive. Herein we review the current knowledge about the role of AMPK activation in thyroid physiology and pathophysiology, with special focus on thyroid cancer.     

Differential phosphodiesterase expression and cytosolic Ca2+ in human CNS tumour cells and in non-malignant and malignant cells of rat origin

A promising attempt in the field of tumour therapy is the modulation of intracellular, proliferation-associated signalling pathways. The role of cyclic nucleotide phosphodiesterases (PDEs), key enzymes in cAMP/cGMP signal transduction, was investigated in two human CNS tumour cell lines as well as in the rat glioblastoma cell line C6 in comparison with rat cerebellar astrocytes with the emphasis on target evaluation. We found differential PDE expression patterns in human CNS tumour cell lines as well as in CNS cells of rat origin. In human glioblastoma cells, intracellular cAMP and Ca(2+) levels correlated well with the PDE expression pattern. There were, however, marked differences in PDE expression and Ca(2+) kinetics between the human glioblastoma cell lines. In contrast to human epithelial tumour cells, shown earlier by us to express significantly enhanced cAMP-specific PDE activity, this was not the case in rat glioblastoma cells compared with non-malignant rat astrocytes. Despite different levels of PDE1 and PDE4 expression and activity, cyclic nucleotide and Ca(2+) levels in non-malignant and malignant rat CNS cells were similar. These in vitro data do not support the concept of PDE1C representing a target exploitable for drug treatment of malignant CNS tumours.     

CD133: holy of grail of neuro‐oncology or promiscuous red‐herring?

The CD133 glycoprotein is a controversial cancer stem cell marker in the field of neuro‐oncology, based largely on the now considerable experimental evidence for the existence of both CD133+ve and CD133?ve populations as tumour‐initiating cells. It is thought that decreasing oxygen tension enhances the complex regulation and phenotype of CD133 in glioma. In light of these ideologies, establishing the precise functional role of CD133 is becoming increasingly critical. In this article, we review the complex regulation of CD133 and its extracellular epitope AC133, and associated alterations, to tumour cell behaviour by hypoxia. Furthermore, its role in functional modulation of tumours, rather than determination of a specific stem cell type is therefore alluded to, while evidence for and against its ability as a cancer stem cell marker in primary brain tumours, is critically evaluated. Thus, the suggestion that CD133 may be a central ‘holy grail’ in identifying core cells for propagation of malignant glial neoplasms seems increasingly less convincing. It remains to be seen, however, whether CD133 is randomly expressed on such brain tumour cell populations or whether it is of major significance to brain biological behaviour.     

T-cell responses at the host: tumour interface

The evidence considered here reinforces the conclusion that T-cell responses to tumours involve complex cellular interactions. An attempt to summarize some of these interactions is shown. This emphasizes that not only are the interactions between the effector cell populations complicated, but that the target cell surface is also subject to variation and modification as a result of the immune response. A feature that also emerges from these studies is that most cells apparently responding to or infiltrating a tumour do not necessarily participate in its destruction, and it is in this area that experimental tumour systems have particular value. This also perhaps explains the preoccupation of experimentalists with the identification of 'the' effector cell crucial to tumour rejection. However, there is heterogeneity between systems in terms of the type of rejection response induced, but a logical basis for this heterogeneity is not established. If experimental studies could define the nature of the immune response generated by a tumour in the context of the biological features of the tumour itself, this could lead to the prediction of the immunogenicity and potential for induction of a rejection response for that tumor. Clearly, experimental tumour systems do not provide an exact reflection of the situation with human tumours. However, they may provide systems that illuminate particular aspects of the human response, and give precedents to guide the interpretation of data derived from human systems. This form of assessment is still at an early stage, but developments in the experimental field should provide a framework for the development and exploitation of T-cell responses to tumours.     

IN VITRO AND IN VIVO LABELLING OF ANIMAL TUMOURS WITH TRITIATED THYMIDINE

The labelling indices obtained by incubating tumour specimens with tritiated thymidine in vitro under hyperbaric oxygen have been compared with those obtained by labelling a matched tumour in vivo. The correspondence between these individual labelling indices is sometimes very poor; however, the average labelling index derived from groups of tumours labelled in the two ways does not differ significantly. There was a large variation from field to field within any tumour, and considerable variation from one tumour to another within each tumour type. The mitotic index was also compared in the matched tumour preparations; the mitotic index in vitro was almost always considerably lower than the values observed in vivo.     

Characterisation of the cell line HC-AFW1 derived from a pediatric hepatocellular carcinoma

Current treatment of paediatric hepatocellular carcinoma (HCC) is often inefficient due to advanced disease at diagnosis and resistance to common drugs. The aim of this study was to generate a cell line derived from a paediatric HCC in order to expand research in this field. We established the HC-AFW1 cell line from a liver neoplasm of a 4-year-old boy through culturing of primary tumor specimens. The cell line has been stable for over one year of culturing and has a doubling time of 40 h. The tumour cells have an epithelial histology and express HCC-associated proteins such as Alpha-fetoprotein (AFP), Glypican 3, E-cadherin, CD10, CD326, HepPar1 and Vimentin. Forty-nine amino acids in exon 3 of β-Catenin that involve the phosphorylation sites of GSK3 were absent and β-Catenin is detectable in the cell nuclei. Cytogenetic analysis revealed large anomalies in the chromosomal map. Several alterations of gene copy numbers were detected by genome-wide SNP array. Among the different drugs tested, cisplatin and irinotecan showed effective inhibition of tumour cell growth in a proliferation assay at concentrations below 5 μg/ml. Subcutaneous xenotransplantation of HC-AFW1 cells into NOD/SCID mice resulted in fast growing dedifferentiated tumours with high levels of serum AFP. Histological analyses of the primary tumour and xenografts included national and international expert pathological review. Consensus reading characterised the primary tumour and the HC-AFW1-derived tumours as HCC. HC-AFW1 is the first cell line derived from a paediatric HCC without a background of viral hepatitis or cirrhosis and represents a valuable tool for investigating the biology of and therapeutic strategies for childhood HCC.